Science Corporation has raised $400m to expand the rollout of its Prima retinal implant system across Europe and prepare for market entry in the US.

The Series D financing round’s proceeds brings the total funding raised by the company since its establishment in 2021 to over $900m.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Investors participating in the funding round included 885 Capital, Khosla Ventures, PLC Neurotech, Tenet Healthcare, the Ackman Oxman Institute, and Y Combinator, among others.

Science’s Prima is a brain-computer interface (BCI) for restoring form vision, enabling individuals blinded by certain late-stage forms of macular degeneration to read letters, numbers, and words. The device secured a European CE mark in July 2026.

The device is also being prepared for a US launch, where the firm is seeking clearance from the US Food and Drug Administration (FDA) via a humanitarian device exemption (HDE).

Additionally, Science plans to direct funds towards scaling up manufacturing, clinical research, and operational capacity, as well as advancing its biohybrid programme, which combines engineered neurons with biological brain circuitry.

The Prima platform will use a small implant paired with specialised eyewear designed to replace the role of deteriorated photoreceptor cells.

A front-mounted camera and inward-facing projector within the glasses transmit directed light patterns onto the micro-implant, which contains 378 light-activated pixels.

The device is currently under evaluation for geographic atrophy resulting from dry age-related macular degeneration (AMD).

Researchers are also assessing the platform’s suitability for additional inherited retinal conditions, such as retinitis pigmentosa and Stargardt disease.

Earlier this year, Science raised $230m to advance commercial activities for Prima for vision restoration.